abciximab Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 4950 143653-53-6

Description:

MoleculeDescription

Synonyms:

  • abciximab
  • reopro
  • 7E3
A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. It is used in treatment of refractory unstable angina, and for prevention of ischemic complications in patients undergoing percutaneous coronary procedures such as ANGIOPLASTY; ATHERECTOMY; or stenting.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
25 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 16, 1993 FDA CENTOCOR INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Retroperitoneal haemorrhage 145.25 88.20 27 832 2867 53345340
Thrombocytopenia 128.37 88.20 56 803 138671 53209536
Haemorrhage intracranial 99.28 88.20 26 833 13326 53334881

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 438.75 52.49 203 1866 148096 32363361
Pulmonary haemorrhage 187.91 52.49 54 2015 9803 32501654
Haemorrhage intracranial 134.97 52.49 47 2022 15840 32495617
Thrombosis in device 127.12 52.49 32 2037 3502 32507955
Incorrect route of product administration 108.50 52.49 37 2032 11689 32499768
Cardiogenic shock 84.76 52.49 36 2033 20626 32490831
Cardiac tamponade 84.20 52.49 25 2044 5050 32506407
Retroperitoneal haemorrhage 79.24 52.49 21 2048 2807 32508650
Myocardial rupture 68.98 52.49 12 2057 210 32511247
Pericardial haemorrhage 68.15 52.49 19 2050 3067 32508390
Coronary artery thrombosis 64.34 52.49 17 2052 2244 32509213
Oesophageal ulcer haemorrhage 64.05 52.49 11 2058 178 32511279
Mallory-Weiss syndrome 61.60 52.49 15 2054 1427 32510030
Haemorrhage 52.71 52.49 35 2034 49413 32462044

Pharmacologic Action:

SourceCodeDescription
ATC B01AC13 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
MeSH PA D000925 Anticoagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Percutaneous coronary intervention indication 415070008

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-IIb/beta-3 Adhesion ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D02778 KEGG_DRUG
4020901 VUID
N0000148393 NUI
4020901 VANDF
CHEMBL1201584 ChEMBL_ID
6584 IUPHAR_LIGAND_ID
7200 INN_ID
DB00054 DRUGBANK_ID
X85G7936GV UNII
152293 RXNORM
1007 MMSL
4116 MMSL
d03811 MMSL
004907 NDDF
108974006 SNOMEDCT_US
386951001 SNOMEDCT_US
D000077284 MESH_DESCRIPTOR_UI
C0288672 UMLSCUI

Pharmaceutical products:

None